With its flagship drug being under substantial price cut, CSPC Pharma is focusing on differentiated and innovative product pipeline and collaboration with leading biotech companies to boost future growth.
CSPC Pharma plans to launch over 30 innovative and over 60 generic drugs during 2021–2025. New products are expected to contribute RMB 1 billion revenue in 2022.
Through November, CSPC announced four business development deals for in-licensing four products targeting multiple therapeutic areas for a combined upfront payment of over RMB 300 million.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.